Company
Headquarters: Beijing, China
Employees: 18,764
CN¥54.79 Billion
CNY as of Jan. 1, 2025
US$7.51 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang series, Tongren Niuhuang Qingxin series, Tongren Dahuoluo series, Yufeng Ningxin dripping pills, Hemiplegia recovery pills, etc. The company is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥17.96 B |
| EBITDA | CN¥3.18 B |
| Gross Profit TTM | CN¥8.45 B |
| Profit Margin | 9.07% |
| Operating Margin | 14.83% |
| Quarterly Revenue Growth | 2.40% |
Beijing Tongrentang Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600085 wb_incandescent